Multiple studies have now demonstrated enhanced efficacy of targeting the MAPK pathway in combination with either Src or PI3K pathway inhibitors in thyroid cancer10–12,18–21, and importantly, our data suggests that Src can also regulate the PI3K pathway in thyroid cancer. The gene discussed is SRC; the disease is thyroid cancer.